Profile
DrugBank provides a comprehensive AI-powered platform for biopharma companies to connect and analyze data on drugs, targets, diseases, and trials.
DrugBank, founded in Dr. Wishart's lab at the University of Alberta, began as a research project to provide structured datasets to academic researchers. The company transitioned to commercialization in response to surging demand from pharmaceutical firms, leveraging its AI-powered knowledgebase to connect relationships across drugs, targets, diseases, trials, and companies.
DrugBank's platform serves as a critical tool for biopharma R&D, offering APIs, intelligence interfaces, and AI/ML-ready datasets. The company has grown significantly, supporting customers in over 24 countries, including 13 of the top 20 pharmaceutical firms. In 2022, DrugBank secured $9M CAD in seed funding led by Brightspark Ventures, with participation from Amplitude Ventures and Theodorus Investment Funds.
The company's impact is evident in its 12M+ global users annually and over 26,000 citations in academic publications. DrugBank's headquarters remain in Edmonton, Canada, benefiting from the region's AI innovation ecosystem anchored by the University of Alberta and the Alberta Machine Intelligence Institute (Amii).
Who buys this
- Pharmaceutical companies
- Biotech firms
- Academic researchers
- Clinical trial organizations
- Data science and informatics teams
Publicly disclosed clients
- Nippon Shinkyaku
- NIH
- Servier
- Bayer
- Healx
- Milner Therapeutics Institute
- Molecular Health
Strengths and what to watch
Strengths
- Extensive, gold-standard knowledgebase with over 160 million data points
- Trusted by 13 of the top 20 pharmaceutical companies globally
- Strong academic foundation with over 26,000 citations in publications
Watch for
- High dependency on AI/ML models, which may face scrutiny for bias or accuracy
- Competition from other data providers and AI-driven biopharma platforms
- Potential challenges in scaling operations while maintaining data quality
Key Information
- Founded
- 2014
- Headquarters
- Edmonton, Canada
Frequently Asked Questions
What is DrugBank used for?
DrugBank provides an AI-powered platform connecting drug, target, disease, and clinical trial data for biopharma research. Used by 13 top pharmaceutical firms, it offers structured datasets and APIs to accelerate drug discovery. The platform processes 160M+ data points, serving academic and commercial researchers globally.
Who owns DrugBank?
Originating from Dr. Wishart's lab at the University of Alberta, DrugBank transitioned to commercial operations serving biopharma firms. In 2022, it secured $9M CAD in seed funding led by Brightspark Ventures, with participation from Amplitude Ventures and Theodorus Investment Funds.
Which companies use DrugBank?
Notable DrugBank clients include Bayer, NIH, and Servier among 13 top-20 pharmaceutical firms. The platform serves biotech companies, academic researchers, and clinical trial organizations across 24 countries. Over 12M users annually access its data, cited in 26,000+ academic publications.
How accurate is DrugBank's data?
DrugBank maintains a gold-standard knowledgebase with 160M+ curated data points, widely cited in peer-reviewed research. However, users should validate AI-generated insights, as machine learning models may inherit biases from training data. The platform undergoes continuous refinement through academic and industry collaboration.
Does DrugBank offer APIs for researchers?
Yes, DrugBank provides APIs and machine-learning-ready datasets for integrating drug-target-disease relationships into research workflows. These tools help pharmaceutical and biotech teams analyze compound interactions, accelerating discovery pipelines while maintaining data provenance from its academically grounded knowledgebase.
What are alternatives to DrugBank?
Competitors include commercial drug databases and open-source alternatives, though DrugBank differentiates with AI-driven relationship mapping and strong academic roots. Users should compare coverage depth (160M+ points), API flexibility, and adoption rates (26K citations) when evaluating platforms for biopharma research needs.
Sources
- www.prnewswire.com — $9M CAD seed funding round led by Brightspark Ventures
- go.drugbank.com — DrugBank's product offerings and customer base
- www.prnewswire.com — DrugBank's presence in the pharmaceutical sector
- www.businesswire.com — DrugBank's role in GPCR-related drug discovery